Abbott Laboratories (NYSE:ABT) Shares Sold by CreativeOne Wealth LLC

CreativeOne Wealth LLC reduced its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 37.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,600 shares of the healthcare product maker's stock after selling 8,156 shares during the quarter. CreativeOne Wealth LLC's holdings in Abbott Laboratories were worth $1,538,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Redwood Park Advisors LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $25,000. Noble Wealth Management PBC purchased a new position in Abbott Laboratories in the 4th quarter valued at about $26,000. NewSquare Capital LLC boosted its holdings in Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after buying an additional 105 shares during the last quarter. WealthTrak Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $28,000. Finally, Rialto Wealth Management LLC purchased a new position in Abbott Laboratories in the 4th quarter valued at $29,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Down 0.3 %

Shares of NYSE:ABT traded down $0.34 during trading on Monday, hitting $130.64. 877,474 shares of the company were exchanged, compared to its average volume of 7,165,996. The firm's 50 day moving average price is $130.62 and its 200-day moving average price is $121.96. The stock has a market capitalization of $226.57 billion, a P/E ratio of 17.08, a PEG ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. On average, research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 1.81%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 30.61%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Stifel Nicolaus increased their target price on shares of Abbott Laboratories from $135.00 to $145.00 and gave the company a "buy" rating in a research report on Thursday. Royal Bank of Canada upped their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a report on Thursday. UBS Group raised their target price on Abbott Laboratories from $146.00 to $148.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Bank of America raised their price target on Abbott Laboratories from $133.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Finally, Evercore ISI boosted their price target on shares of Abbott Laboratories to $136.00 and gave the stock a "buy" rating in a research note on Thursday, January 2nd. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $142.59.

Insider Activity

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the company's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the completion of the transaction, the executive vice president now owns 125,697 shares of the company's stock, valued at $16,152,064.50. This represents a 15.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the sale, the executive vice president now directly owns 71,928 shares of the company's stock, valued at $9,625,404.96. This represents a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock worth $15,463,316 over the last ninety days. 0.46% of the stock is currently owned by insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.